Federal government undermines COVID-19 vaccine development
Canada’s amended Patent Act weakens protections for intellectual property in the life sciences just when rights are vital for mobilizing a rapid response
Read More
Author: Kristina Acri
USMCA will stunt potentially lifesaving innovation
The new trade agreement represents progress for international trade, but crucially, it weakens protections for the biopharma industry
Read More
Trudeau pharmacare could limit drug access, hurt patients
Canada must cautiously approach any policy change that puts patients, innovation and innovative industries at risk
Read More
Canada can learn from Swiss and Dutch drug coverage
Both countries partner with the private sector and expect patients to share the cost of treatment
Read More
National pharmacare can hurt patients more than it helps
Will likely result in reduced access to new drugs, and delay research and development
Read More
Increase in counterfeit drugs a danger to Canadians
As the trade in counterfeit drugs grows, so do the risks to Canadian patients and the costs to legitimate manufacturers
Read More
Inadequate intellectual property rights protections hurt patients, economy
Provide biopharmaceutical firms with patent term extensions to recover time lost due to mandatory governmental regulatory and marketing approvals
Read More
Stronger IP protection for biologic medicine could save lives
Biologic medicines are difficult and expensive to develop, and Canadia’s weak intellectual property protections are making it even harder
Read More